SynAct Pharma AB (STO:SYNACT)

Sweden flag Sweden · Delayed Price · Currency is SEK
17.16
+0.28 (1.66%)
Mar 23, 2026, 3:47 PM CET
Market Cap945.31M +11.0%
Revenue (ttm)n/a
Net Income-110.83M
EPS-2.17
Shares Out56.00M
PE Ration/a
Forward PE16.55
Dividendn/a
Ex-Dividend Daten/a
Volume355,515
Average Volume234,862
Open16.56
Previous Close16.88
Day's Range16.00 - 17.32
52-Week Range13.40 - 25.30
Beta1.01
RSI33.45
Earnings DateApr 15, 2026

About SynAct Pharma AB

SynAct Pharma AB, a clinical stage biotechnology company, researches and develops medicines for the treatment of inflammatory diseases in Sweden. The company develops AP1189, a drug candidate in Phase 2 clinical trial for the treatment of rheumatoid arthritis, idiopathic membranous nephropathy, and virus-induced respiratory insufficiency. It is also developing TXP-11, an advanced peptide agonist that is in preclinical trials for the prevention of organ failure in surgery; and various drug programs to treat auto-immune and inflammatory diseases.... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2012
Employees 8
Stock Exchange Nasdaq Stockholm
Ticker Symbol SYNACT
Full Company Profile

Financial Performance

Financial Statements